A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
David A BondYing HuangBeth A ChristianSamantha M JaglowskiDon BensonLapo AlinariRobert A BaiocchiJonathon B CohenKristie A BlumKami J MaddocksPublished in: Leukemia & lymphoma (2022)